Bid defense meetings are where sponsors validate a CRO's proposal before signing anything. This is the moment to stress-test claims, not just nod along to a polished slide deck. Ask the wrong questions—or none at all—and you risk a costly mismatch that surfaces six months into the trial.
This guide covers 15 essential questions spanning experience, operational capability, quality systems, team structure, and commercial terms.
Key Takeaways
- CRO selection goes beyond price: probe therapeutic experience, regulatory track record, and operational transparency
- Use bid defense to stress-test assumptions before signature and surface gaps pricing alone will miss
- Cover five question categories: experience, operations, quality/compliance, team communication, and commercial terms
- Global reach paired with localized regulatory proficiency reduces risk in multi-regional trials
What Is CRO Selection and Bid Defense?
CRO selection is the sponsor's process of evaluating and choosing a research partner for clinical trial execution, covering everything from RFP issuance to final contract signature.
Bid defense is the formal meeting where shortlisted CROs present and justify their proposal: budget, timeline, staffing, and methodology. It's the sponsor's opportunity to pressure-test claims before committing.
Why This Process Matters
A flawed selection process creates downstream problems. Direct trial-conduct costs run approximately $40,000 per day, and unrealized prescription sales can add roughly $800,000 per day in commercial exposure during delays, according to Tufts Center for the Study of Drug Development.
Bid defense sessions expose gaps between a polished proposal and actual operational readiness. Clinical Leader's oversight research flags recurring risks that often stay hidden until you ask direct questions:
- Immature systems and processes
- Insufficient therapeutic or operational experience
- Inadequate staffing plans
Core Questions on Experience and Therapeutic Expertise
These questions determine whether the CRO has genuine, proven experience for your specific phase, indication, and geography, not just adjacent experience they're stretching to fit.
Question 1: What is your experience running trials in our specific therapeutic area and phase? Indication-specific experience reduces protocol design errors and site startup delays. A CRO that's run twenty oncology trials isn't automatically qualified for your rare-disease pediatric study.
Question 2: Can you provide case studies or references from similar past trials? References validate claims and reveal how the CRO handled real-world setbacks, not only their successes.
Question 3: What is your track record with multi-regional or emerging market trials? This matters for sponsors expanding into LMICs or navigating diverse regulatory bodies. Regulatory and cultural differences across regions demand localized proficiency.
Question 4: How many ongoing trials does your team currently manage, and what is your current bandwidth? Overextended teams are a leading cause of missed milestones. Ask for actual numbers, not vague reassurances.
Question 5: What is your site identification and patient recruitment strategy for our target population? Recruitment delays still sink timelines across the industry. In a study of 2,542 surgical trials, only 45.9% met their prespecified enrollment target, and just 20.4% finished within the planned timeframe, per JAMA Network Open.
Core Questions on Operational Capability and Quality Systems
These questions dig into how the CRO will actually execute the trial day-to-day, not how they describe it in marketing materials.
Question 6: What is your quality management system, and what GxP standards do you adhere to? GCP, GLP, or GMP compliance requirements shift depending on trial phase. Confirm the CRO knows the difference and applies the right standard to your study.
Question 7: How do you manage data integrity and clinical data management processes? Data lock accuracy, audit trails, and 21 CFR Part 11-ready electronic records are non-negotiable for FDA submissions. Ask about eCRF programming, SDTM conversion, query management, and database lock timelines.
Question 8: What is your risk management and issue escalation process? Ask who owns first response when deviations, adverse events, or delays occur, what escalation path reaches the sponsor, and what written timelines they commit to.
Question 9: How do you ensure regulatory compliance across multiple jurisdictions? Essential for multi-regional clinical trials (MRCTs). Confirm prior work with the authorities your protocol will touch, how they reconcile conflicting requirements, and whether dedicated local regulatory leads stay assigned through submission.
Question 10: What technology platforms do you use for EDC, CTMS, and safety reporting? Outdated or incompatible systems create integration bottlenecks with your existing infrastructure. Ask specifically how their platforms talk to yours.
Question 11: What is your process for vendor and third-party oversight? Subcontracted work (labs, imaging, central pharmacy) still falls under the CRO's quality accountability. Ask them to walk through:
- Vetting criteria for third-party vendors before engagement
- Audit frequency for subcontracted work
- Accountability ownership when a vendor error occurs
Questions on Team, Communication, and Project Management
These questions reveal how transparent and accountable the CRO will be once the contract is signed.
Question 12: Who will be our dedicated project lead, and what is their availability and experience? Named, experienced leads reduce turnover-related disruptions. A bid-defense red flag: the team presenting isn't the team that shows up on day one. Confirm the lead by name, percent allocation, and relevant trial experience before award.
Question 13: What is your communication cadence and escalation pathway for sponsors? Unclear communication structures cause avoidable delays and sponsor frustration. Get specifics on:
- Weekly or biweekly status calls
- Dedicated channel or portal for day-to-day issues
- Named escalation contacts and response timelines
Question 14: How do you handle staff turnover or team changes mid-trial? Continuity planning matters. CRA turnover, while improving, still sat at a median of 22% in 2024, down from 30% in 2022, according to BDO's clinical research turnover survey.
That's still roughly one in five CRAs changing roles annually. Ask how the CRO handles knowledge transfer, backup coverage, and sponsor notification when it happens.
Questions on Commercial Terms and Timeline Commitments
The final category covers cost transparency and accountability, where vague answers cause the most disputes later.
Question 15: How is your budget structured, and what triggers change orders or cost overruns? Vague change-order policies are a common source of budget disputes. Push for specifics on:
- What scope changes automatically trigger a change order
- How overruns get communicated and approved
- Whether unit-based or milestone-based pricing applies
Also press for timeline commitments:
- How milestones are defined, tracked, and reported
- What remedies apply when dates slip
- Whether the CRO accepts financial consequences for delays
A CRO that offers only "best effort" language on timelines is signaling weak accountability and higher program risk.
How DRK Research Solutions Can Help
DRK Research Solutions supports sponsors through transparent bid defense processes backed by over a decade of multi-regional trial experience. Since expanding into multi-regional clinical trials in 2018, DRK has built an active footprint across Europe, the Middle East, Asia, Africa, and the Americas, pairing global reach with local regulatory knowledge.
What sponsors get with DRK:
- Full-service CRO support from first-in-human studies through late-phase development and regulatory submission
- 100+ professionals across clinical operations, data management, biostatistics, and regulatory affairs
- GxP-compliant quality systems for Phase II–IV trials and generics/hybrid product development
- Patient-centric focus on underserved and LMIC populations, rooted in DRK's origins as a patient advocacy organization
Sponsors evaluating CRO partners can schedule a consultation to walk through DRK's proposal process directly.
Conclusion
These 15 questions help you confirm that a CRO's staffing, systems, and regulatory reach genuinely match your trial's complexity and timeline.
Treat bid defense as an ongoing accountability checkpoint, not a one-time gate. The strongest sponsor-CRO relationships revisit these same questions periodically throughout the partnership, not just before signature.
Frequently Asked Questions
What questions should I ask a CRO?
Cover the five categories outlined above: experience, operational capability, quality and compliance, communication, and commercial terms. Within those, press on therapeutic experience, quality systems, team continuity, and cost transparency.
What are the top 5 questions to ask a candidate?
Focus on: therapeutic/phase-specific experience, verifiable references, your dedicated project lead's availability, their data management approach, and how their budget/change-order structure works.
What is the difference between CRO selection and bid defense?
CRO selection is the broader evaluation process, from RFP to contract signature. Bid defense is the specific meeting where shortlisted CROs present and justify their proposal in detail.
How long does a typical CRO bid defense process take?
A bid defense meeting usually runs half a day to a full day. The full selection process, from shortlisting to decision, typically takes 8 to 12 weeks, depending on candidate count and responsiveness, according to Halloran Consulting Group. Complex multi-regional trials often take longer.
What red flags should sponsors watch for during bid defense?
Watch for vague answers on staffing plans, unclear change-order policies, and a lack of therapeutic-specific references. A team swap after contract signing is a well-documented warning sign.
Why is multi-regional experience important when selecting a CRO?
Regulatory requirements and cultural expectations vary significantly across regions. A CRO without localized proficiency risks delays navigating unfamiliar approval pathways or site-level cultural dynamics.
